Yahoo
XETRA - Delayed Quote EUR

Medios AG (ILM1.DE)

10.94 +0.36 (+3.40%)
As of 3:44:38 PM GMT+1. Market Open.
Chart Range Bar
Loading chart for ILM1.DE
  • Previous Close 10.58
  • Open 10.60
  • Bid 10.90 x --
  • Ask 10.96 x --
  • Day's Range 10.50 - 11.02
  • 52 Week Range 9.98 - 17.44
  • Volume 33,951
  • Avg. Volume 33,359
  • Market Cap (intraday) 279.033M
  • Beta (5Y Monthly) 1.34
  • PE Ratio (TTM) 23.78
  • EPS (TTM) 0.46
  • Earnings Date Nov 10, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 20.25

Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment also includes cytostatic preparations, antibody therapies, and parenteral nutrition solutions. The International Business International covers all activities in the international environment from the procurement of Active Pharmaceutical Ingredients, the sterile and non-sterile drugs and the supply of public and hospital pharmacies through homecare service. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. Medios AG was founded in 2015 and is headquartered in Berlin, Germany.

www.medios.ag

989

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .

YTD Return

ILM1.DE
24.45%
DAX P (^GDAXI)
5.83%

1-Year Return

ILM1.DE
10.33%
DAX P (^GDAXI)
8.19%

3-Year Return

ILM1.DE
28.31%
DAX P (^GDAXI)
71.16%

5-Year Return

ILM1.DE
70.31%
DAX P (^GDAXI)
62.46%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY25
Revenue 538.28M
Earnings --
Profit Margin 0.00%

Q2

FY24

Q3

FY24

Q1

FY25

Q3

FY25

0
100M
200M
300M
400M
500M
0.0%

Analyst Insights

View More

Analyst Price Targets

16.00
20.25 Average
10.94 Current
23.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.52%

  • Return on Assets (ttm)

    2.64%

  • Return on Equity (ttm)

    2.14%

  • Revenue (ttm)

    2.16B

  • Net Income Avi to Common (ttm)

    11.19M

  • Diluted EPS (ttm)

    0.46

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    84.58M

  • Total Debt/Equity (mrq)

    38.21%

  • Levered Free Cash Flow (ttm)

    23.02M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: